Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.
Lab monitoring recommendations for patients taking XELJANZ |
|||
---|---|---|---|
At initiation |
After 4 to 8 weeks |
Every 3 months thereafter |
|
Lymphocytes |
|
||
Neutrophils |
|||
Haemoglobin |
|||
Lipids |
After 8 weeks following initiation of therapy |
||
Liver enzymes |
Routine monitoring of liver test and prompt investigation of the cause of liver enzyme elevation are also recommended |
||
Avoid initiating treatment in patients with: |
Absolute lymphocyte count <0.75 x109 cells/L |
Absolute neutrophil count <1.0 x109 cells/L |
Haemoglobin levels |
Lab monitoring recommendations for patients taking XELJANZ 1 |
|
---|---|
Lymphocytes |
|
At initiation |
|
After 4 to 8 weeks |
|
Every 3 months thereafter |
|
Neutrophils |
|
At initiation |
|
After 4 to 8 weeks |
|
Every 3 months thereafter |
|
Haemoglobin |
|
At initiation |
|
After 4 to 8 weeks |
|
Every 3 months thereafter |
|
Lipids |
|
At initiation |
|
After 4 to 8 weeks |
After 8 weeks following initiation of therapy |
Every 3 months thereafter |
|
Liver enzymes |
|
At initiation |
Routine monitoring of liver test and prompt investigation of the cause of liver enzyme elevation are also recommended |
After 4 to 8 weeks |
|
Every 3 months thereafter |
|
Avoid initiating treatment in patients with: |
|
At initiation |
Absolute lymphocyte count <0.75 cells x109/L |
After 4 to 8 weeks |
Absolute neutrophil count <1.0 x109 cells/L |
Every 3 months thereafter |
Haemoglobin levels |
Please refer to the full PI for recommended dose modifications based on changes in lab tests.
Explore the resources avaliable for patients who have been prescribed XELJANZ for PsA
Visit page
*XELJANZ 5 mg BID is the only approved dosage for the treatment of PsA, which should not be exceeded. 10 mg is not licensed for PsA.
XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?